PT - JOURNAL ARTICLE AU - Pinal-Fernandez, Iago AU - Muñoz-Braceras, Sandra AU - Casal-Dominguez, Maria AU - Pak, Katherine AU - Torres-Ruiz, Jiram AU - Musai, Jon AU - Dell’Orso, Stefania AU - Naz, Faiza AU - Islam, Shamima AU - Gutierrez-Cruz, Gustavo AU - Cano, Maria Dolores AU - Matas-Garcia, Ana AU - Padrosa, Joan AU - Tobías-Baraja, Esther AU - Garrabou, Gloria AU - Aldecoa, Iban AU - Espinosa, Gerard AU - Simeon-Aznar, Carmen Pilar AU - Guillen-Del-Castillo, Alfredo AU - Gil-Vila, Albert AU - Trallero-Araguas, Ernesto AU - Christopher-Stine, Lisa AU - Lloyd, Thomas E. AU - Liewluck, Teerin AU - Naddaf, Elie AU - Stenzel, Werner AU - Greenberg, Steven A. AU - Grau, Josep Maria AU - Selva-O’Callaghan, Albert AU - Milisenda, Jose C. AU - Mammen, Andrew L. TI - Pathogenic autoantibody internalization in myositis AID - 10.1101/2024.01.15.24301339 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.15.24301339 4099 - http://medrxiv.org/content/early/2024/01/17/2024.01.15.24301339.short 4100 - http://medrxiv.org/content/early/2024/01/17/2024.01.15.24301339.full AB - Objectives Myositis is a heterogeneous family of autoimmune muscle diseases. As myositis autoantibodies recognize intracellular proteins, their role in disease pathogenesis has been unclear. This study aimed to determine whether myositis autoantibodies reach their autoantigen targets within muscle cells and disrupt the normal function of these proteins.Methods Confocal immunofluorescence microscopy was used to localize antibodies and other proteins of interest in myositis muscle biopsies. Bulk RNA sequencing was used to study the transcriptomic profiles of 668 samples from patients with myositis, disease controls, and healthy controls. Antibodies from myositis patients were introduced into cultured myoblasts by electroporation and the transcriptomic profiles of the treated myoblasts were studied by bulk RNA sequencing.Results In patients with myositis autoantibodies, antibodies accumulated inside myofibers in the same subcellular compartment as the autoantigen. Each autoantibody was associated with effects consistent with dysfunction of its autoantigen, such as the derepression of genes normally repressed by Mi2/NuRD in patients with anti-Mi2 autoantibodies, the accumulation of RNAs degraded by the nuclear RNA exosome complex in patients with anti-PM/Scl autoantibodies targeting this complex, and the accumulation of lipids within myofibers of anti-HMGCR-positive patients. Internalization of patient immunoglobulin into cultured myoblasts recapitulated the transcriptomic phenotypes observed in human disease, including the derepression of Mi2/NuRD-regulated genes in anti-Mi2-positive dermatomyositis and the increased expression of genes normally degraded by the nuclear RNA exosome complex in anti-PM/Scl-positive myositis.Conclusions In myositis, autoantibodies are internalized into muscle fibers, disrupt the biological function of their autoantigen, and mediate the pathophysiology of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded, in part, by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All biopsies were from subjects enrolled in institutional review board (IRB)-approved longitudinal cohorts in the National Institutes of Health, the Johns Hopkins, the Clinic Hospital, the Vall d'Hebron Hospital, the Mayo Clinic, and the Charite-Universitatsmedizin Berlin.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAny anonymized data not published within the article will be shared by request from any qualified investigator.